Engineering Next-Gen Treg Therapies

Redefining treatment for transplantation and autoimmunity with next-generation cellular therapies.

Get in touch
CAR-Treg cells interacting with other cells, capturing ligands through trogocytosis. Engineered CAR-Tregs acquiring activation ligands from neighboring cells via trogocytosis.

Building scalable, precise, and durable Treg therapies to solve complex immune challenges.

Our Mission

At Regatta Bio, we are advancing the next generation of regulatory T cell (Treg) therapies to address some of the most pressing challenges in immune health. Our mission is to develop scalable, targeted, and durable treatments for conditions like chronic Graft-versus-Host Disease, solid organ rejection, and autoimmune disorders by overcoming the limitations of traditional immunosuppression.
Proprietary platform enabling potent, precisely engineered Treg therapies.
World-class team with leading experts in immune tolerance and clinical translation.
Clinic-ready pipeline supported by strong data and GMP production.
Scalable vision targeting autoimmunity and transplantation with a de-risked path.

Reimagining immune therapies to address the unmet needs in transplantation and autoimmunity

An imbalance of Teffector/Treg cells leads to autoimmunity
Teffector
Treg
Graphical representation of Tolerance and Autoimmunity using scales. For Tolerance, Teffectors and Tregs are balanced. For autoimmunity, Teffectors outweigh Tregs.

Regulatory T Cells (Tregs) control autoimmunity through multiple mechanisms.

  • Immune Suppression via Cytokines
  • Metabolic Disruption
  • Modulation of APCs
  • Direct Cytolysis and Immune Inhibition
Despite decades of progress, immune-driven conditions like chronic GvHD, transplant rejection, and autoimmunity remain underserved, often treated with blunt immunosuppression that risks long-term harm. Regatta Bio is advancing precision Treg therapies to bring safer, more durable immune tolerance to patients in need.
Cell transplants
Donor-derived Tregs can re-set the balance between graft and host in blood stem cell transplants and other conditions
Organ transplants
Boosting autologous Tregs can overcome the risk of graft rejection while lowering the need for immunosuppressive drugs.
Autoimmune diseases
Increasing the supply of the body's natural immune regulatory cell can be key to many autoimmune conditions
Inflammatory conditions
Tregs can dampen local and systemic inflammatory conditions leading to faster healing and better outcomes

(coming soon)

Our pipeline is designed to address current treatment gaps with highly differentiated and scalable cell therapies.

01
EVE Tregs (v1.0)
Ex vivo expanded, non-genetically modified Tregs. High-purity, stable phenotype, and scalable manufacturing.
02
Engineered OX40L CAR-Tregs (v2.1)
Genetically modified to express OX40L-specific CAR for improved antigen targeting and alloreactivity control. Engineered for IL-2 independence, enabling persistence without exogenous IL-2.
03
CNI-Resistant CAR-Tregs (v2.2)
Engineered to resist suppression by calcineurin inhibitors (e.g., cyclosporin), enabling therapeutic performance even under standard immunosuppressive regimens.

Team

Regatta Bio was founded by pioneers in transplantation and immune tolerance, including Dr. Leslie Kean, a leading physician-scientist who led the clinical trials behind abatacept’s FDA approval. The company is supported by a world-class scientific advisory board with deep expertise across immunology, cell therapy, and clinical research, and is jointly incubated by Eos BioInnovation and Panacea Venture.
Focused on restoring immune balance through Treg-based therapies
Founded by pioneers in transplantation and immune tolerance
Committed to solving urgent, unmet clinical needs
mosaic of team members. Top row from left to right: Leslie Kean, Susan Prockop, Holly Wobma. Middle row from left to right: Xianliang Rui, Bruce Blazar, David Scadden. Bottom row from left to right: Joren Madsen, Len Zon, Brock Reeve.

Get in touch

Whether you're advancing science in immune tolerance or exploring impactful investment in next-generation cell therapies, we welcome collaboration that helps bring transformative treatments to patients in need.
Contact details
Address
One Broadway
Cambridge, MA
02142
Thank you, we have received your request and will be in touch shortly.
Oh no! Something went wrong while submitting the form. Please try again.